Author(s): Calabrese M, De Stefano N,Atzori M,Bernardi V,Mattisi I, et al.
Background:A significant inflammatory pathologic disorder in the cortex of patients with multiple sclerosis (MS) has been demonstrated by ex vivo studies.
Objective:To determine the frequency, time of appearance, and clinical relevance of intracortical lesions (ICLs) in MS in vivo.
Design:Double inversion recovery sequence study.
Setting:Multiple Sclerosis Centre of the Veneto Region. Patients We enrolled 380 patients (116 with clinically isolated syndrome [CIS], 163 with relapsing-remitting MS [RRMS], and 101 with secondary progressive MS [SPMS]) and 40 age- and sex-matched healthy volunteers between May 1, 2005, and December 31, 2006.
Main outcome measures:We assessed the frequency and number of ICLs and brain parenchyma fraction, white matter T2 lesion volume, and clinical disability.
Results:Although never observed in healthy volunteers, ICLs were detected in 58% of patients (36% of patients with CIS, 64% of patients with RRMS, and 73% of patients with SPMS). The number of ICLs was higher in patients with SPMS than in those with CIS or RRMS (P <.001), and patients with ICLs had a higher Expanded Disability Status Scale score (P = .004), a higher white matter T2 lesion volume (P = .008), a lower brain parenchyma fraction (P = .009), and a higher frequency of IgG oligoclonal bands (IgGOBs) (P <.001) than patients without ICLs. Patients positive for IgGOBs had more ICLs than patients negative for IgGOBs (P = .02). The number of ICLs correlated with the Expanded Disability Status Scale score (r = 0.48, P <.001), white matter T2 lesion volume (r = 0.38, P = .001), and brain parenchyma fraction (r = -0.47, P = .001). A significant association between ICLs and male sex was observed.
Conclusions:Although more frequent in patients with SPMS, ICLs were observed from the early disease stages. The ICLs were more frequently detected in patients with IgGOBs and were associated with a higher clinical disability score and male sex. The ICLs may help to define MS clinical heterogeneity and prognosis in clinical settings.
Referred From: https://pubmed.ncbi.nlm.nih.gov/17923625/
Author(s): Foundas AL, Weisberg A, Browning CA, Weinberger DR
Author(s): Geurts J, Roosendaal S, Calabrese M,Ciccarelli O,Agosta F,et al.
Author(s): Meyer JR,Roychowdhury S, Russell EJ, Callahan C,Gitelman D,et al.
Author(s): Achten E, Boon P, De Poorter J,Calliauw L, Van De Kerckhove, et al.
Author(s): Naidich TP,Valavanis AG,Kubik S, Taber Kh,Yasargil MG, et al.
Author(s): Wagner M,Jurcoane A, Hattingen E
Author(s): Sim J, Wright CC
Author(s): Byrt T, Bishop J, Carlin JB
Author(s): Naidich TP,Valavanis AG,Kubik S
Author(s): Seghier ML
Author(s): Ribas GC
Author(s): Rademacher J,Galaburda A, Kennedy D,Filipek P,Caviness V, et al.
Author(s): Ebeling U, Steinmetz H, Huang Y, Kahn T
Author(s): Segal E,Petrides M